Imatinib and the long tail of targeted drug development.,Nature Reviews Clinical Oncology

当前位置： X-MOL 学术 › Nat. Rev. Clin. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Imatinib and the long tail of targeted drug development.
Nature Reviews Clinical Oncology ( IF 81.1 ) Pub Date : 2020-01-01 , DOI: 10.1038/s41571-019-0287-0
Benjamin G Carlisle ₁ , Tiger Zheng ₁ , Jonathan Kimmelman ₁

Affiliation

New molecular insights occasionally lead to the rapid development of therapeutic agents that improve the outcomes of patients with cancer; however, these breakthroughs can be followed by extensive, empirically driven and often unsuccessful efforts at extending the drug to other indications or combinations. Herein, we describe the clinical development of imatinib, a paradigm of rapid molecularly driven drug development, and advocate for a balanced portrayal of the potential of molecularly targeted therapies for cancer.

中文翻译：

伊马替尼和靶向药物开发的长尾。

新的分子见解偶尔会导致治疗药物的快速发展，从而改善癌症患者的预后；然而，在这些突破之后，可以进行广泛的、经验驱动的、通常不成功的努力，将药物扩展到其他适应症或组合。在此，我们描述了伊马替尼的临床开发，这是一种快速分子驱动药物开发的范例，并倡导平衡描绘癌症分子靶向治疗的潜力。

更新日期：2019-10-24

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11